https://doi.org/10.30702/Ophthalmology.2017/07.art7

Serdiuk V. N.^{1, 2}, Pylypenko L. Yu.^{1, 3}

¹Dnipropetrovsk Medical Academy of Health Ministry of Ukraine, Dnipro, Ukraine
²Dnipropetrovsk Regional Clinical Ophthalmology Hospital, Dnipro, Ukraine
³Municipal Polyclinic no 4, Dnipro, Ukraine 

Abstract

Background. Clinical studies indicate an increase of the levels of proinflammatory cytokines, adhesion molecules in the blood serum, activation of immune cells at diabetes and their correlation with the progression of diabetic retinopathy (DRP). 

 Objective. In patients with metabolic syndrome (MS), the concentration of blood circulating interleukin-8 (IL-8) was studied at various stages of DRP and a comparative evaluation of the effect of the factors of the progression of DRP on its content in the blood was performed. Researches were carried out in 64 patients (95 eyes) with MS and DRP (men and women, mean age 61.55 ± 2.37 years, average type 2 diabetes (T2D) length 11.23 ± 2.11 years, mean level of glycated hemoglobin (HbA1C) 9.89 ± 0.78 %, mean BMI 34.55 ± 3.75 kg/m²), which were divided into 3 groups depending on the stage of the DRP.

Methods. The ANOVA and regression analysis were used as statistical analysis. 

 Results. It has been shown that the factor of age of patients (up to 60 years), the duration of diabetes (more than 10 years), the subcompensation of carbohydrate metabolism, and the peculiarity of hypoglycemic therapy (oral administration) have a modifying effect on the level of IL-8 in blood in patients with MS on the proliferative stage of DRP. A statistically significant negative association (r = −0.29, R2 = 8.6 %, p = 0.03) of the level of IL-8 in the blood and the age of the patients and the trend (r = −0.25, R² = 6.3 %; p = 0.06) to the inverse relationship of the duration of T2D and the concentration of IL-8 in the blood of patients with DRP and MS. The conclusion is drawn regarding the association of IL-8 with DRP, especially in patients under 60 years of age.

 Keywords: diabetic retinopathy, interleukin-8, metabolic syndrome.

REFERENCES

1. Zak KP, Mel’nichenko SV, Tronko EN. [The level of circulating cytokines and chemokines in the preclinical and early clinical stage of the development of type 1A diabetes mellitus]. Terapevticheskij arhiv. 2010;10:10–15. (in Russian).
2. Zak KP, Popova VV. [Chemokines with type 1 diabetes mellitus in humans]. Ukr Med Chasopys. 2008;6:69–78. (in Russian).
3. Popova VV, Melnichenko SV, Zak KP, Mankovskij BN. [The level of circulating chemokine − interleukin-8 in the pre-clinical and early clinical stages of type 1 diabetes in children]. Klinichna endokrynolohiia ta endokrynna khirurhiia. 2007;2:38–41. (in Ukrainian).
4. Serdyuk VN, Ishhenko VA. [Morphometrial and biochemical clusters of metabolic syndrome in patients with type 2 diabetes mellitus at different stages of diabetic retinopathy]. Mizhnarodnyi endokrynolohichnyi zhurnal. 2016;7(79):69−74. (in Russian).
5. Chibber R, Ben-Mahmud BM, Coppini D, Christ E, Kohner EM. Activity of the glycosylating enzyme, core 2 GlcNAc (β1,6) transferase, is higher in polymorphonuclear leukocytes from diabetic patients compared with age-matched control subjects: relevance to capillary occlusion in diabetic retinopathy. Diabetes. 2000;49(10):1724–30.
6. Chibber R, Ben-Mahmud BM, Mann GE, Zhang JJ, Kohner EM. Protein kinase C β2-dependent phosphorylation of core 2 GlcNAc-T promotes leukocyte-endothelial cell adhesion: a mechanism underlying capillary occlusion in diabetic retinopathy. Diabetes. 2003;52(6):1519–27.
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486−97.
8. Doganay S, Evereklioglu C, Er H, Türköz Y, Sevinç A, Mehmet N, Savli H. Сomparison of serum NO, TNF-α, IL-1β, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye. 2002;16(2):163–70.
9. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F. Diagnosis and Management of the Metabolic Syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735−52.
10. Hayasaka S, Zhang XY, Cui HS, Yanagisawa S, Chi ZL, Hayasaka Y, Shimada Y. Vitreous Chemokines and Shou (Zheng in Chinese) of Chinese-Korean-Japanese medicine in patients with diabetic vitreoretinopathy. Am. J Chin Med. 2006;34(4):537–43.
11. van Hecke MV, Dekker JM, Nijpels G, Moll AC, Heine RJ, Bouter LM, Polak BC, Stehouwer CD. Inflammation and endothelial dysfunction are associated with retinopathy: the Hoorn study. Diabetologia. 2005;48(7):1300–6.
12. Spijkerman MW, Gall MA, Tarnow L, Twisk JW, Lauritzen E, Lund-Andersen H, Emeis J, Parving HH, Stehouwer CD. Endothelial dysfunction and low-grade inflammation and the progression of retinopathy in type 2 diabetes. Diabetic Medicine. 2007;24(9):969–76.
13. Herder C, Baumert J, Thorand B, Koenig W, de Jager W, Meisinger C, Illig T, Martin S, Kolb H. Chemokines as risk factors for type 2 diabetes: results from the MONICA/KORA Augsburg study, 1984−2002. Diabetologia. 2006;49(5):921–29.
14. Hernández C, Segura RM, Fonollosa A, Carrasco E, Francisco G, Simó R. Interleukin-8, monocyte chemoattractant protein-1 and IL-10 in the vitreous fluid of patients with proliferative diabetic retinopathy. Diabetic Medicine. 2005;22(6):719–722.
15. Inzucchi S, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015; 38(1):140–9.
16. Kaul AH, Tarr JM, Kohner EM, Chibber R. Is inflammation a common retinal-renal-nerve pathogenic link in diabetes? Current Diabetes Reviews. 2010;6(5):294–303.
17. Klein EK, Knudtson MD, Tsai MY, Klein R. The relation of markers of inflammation and endothelial dysfunction to the prevalence and progression of diabetic retinopathy: Wisconsin epidemiologic study of diabetic retinopathy. Archives of Ophthalmology. 2009;127(9):1175–82.
18. Lutty GA, Cao J, McLeod DS. Relationship of polymorphonuclear leukocytes to capillary dropout in the human diabetic choroid. American Journal of Pathology. 1997;151(3):707–14.
19. Schroder S, Palinski W, Chmid-Schonbein GW. Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. American Journal of Pathology. 1991;139(1):81–100.

Received: 20 Nov. 2017

Published: December 2017